SEC Form 4 · accession 0001140361-16-087582
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L Basta
Director
Period of report
Nov 21, 2016
Accepted (ET)
Nov 22, 2016 · 4:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2016 | M | 1,125 | $7.84 | A | 1,125 | D | |
| Common Stock | Nov 21, 2016 | F | 1,026 | $8.5932 | D | 99 | D | |
| Common Stock | Nov 21, 2016 | U | 99 | $8.5932 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $7.84 | Nov 21, 2016 | M | 1,125 | A | — | Jun 6, 2023 | Common Stock | 1,125 | 0 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction.
- F2The option is fully vested and exercisable.